CDT EQUITY INC. Stock-Based Compensation
CDT EQUITY INC. (CDT) reported Stock-Based Compensation of $398.00 thousand for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-08
- CDT EQUITY INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $200.00K, a 25.00% increase year-over-year.
- CDT EQUITY INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $198.00K, a 15.38% decline year-over-year.
- CDT EQUITY INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $211.00K, a 41.71% decline year-over-year.
- CDT EQUITY INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.58M, a 343.26% increase year-over-year.
- CDT EQUITY INC. share-based payment arrangement, noncash expense for fiscal 2023 was $199.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | $398.00K S-1 · filed 2026-09-08 | $609.00K derived: sum of 3 quarters · filed 2026-09-08 | $2.19M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-03-31 | $198.00K 10-Q · filed 2026-07-15 | $409.00K derived: sum of 2 quarters · filed 2026-09-08 | $1.99M derived: sum of 3 quarters · filed 2026-09-08 | $2.15M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-12-31 | $211.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | $1.79M derived: sum of 2 quarters · filed 2026-09-08 | $1.95M derived: sum of 3 quarters · filed 2026-09-08 | $2.18M S-1 · filed 2026-09-08 |
| 2025-09-30 | $1.58M derived: 10-Q 9 month − S-1 6 month · filed 2025-11-13 | $1.74M derived: sum of 2 quarters · filed 2026-09-08 | $1.97M 10-Q · filed 2025-11-13 | $2.33M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-06-30 | $160.00K derived: S-1 6 month − 10-Q 3 month · filed 2026-09-08 | $394.00K S-1 · filed 2026-09-08 | $756.00K derived: sum of 3 quarters · filed 2026-09-08 | $1.11M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-03-31 | $234.00K 10-Q · filed 2026-07-15 | $596.00K derived: sum of 2 quarters · filed 2026-09-08 | $952.00K derived: sum of 3 quarters · filed 2026-09-08 | $1.44M derived: sum of 4 quarters · filed 2026-09-08 |
| 2024-12-31 | $362.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08 | $718.00K derived: sum of 2 quarters · filed 2026-09-08 | $1.20M derived: sum of 3 quarters · filed 2026-09-08 | $1.63M S-1 · filed 2026-09-08 |
| 2024-09-30 | $356.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $839.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.27M 10-Q · filed 2025-11-13 | $1.46M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $483.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-14 | $914.00K 10-Q · filed 2025-08-14 | $1.10M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $431.00K 10-Q/A · filed 2025-08-14 | $620.00K derived: sum of 2 quarters · filed 2025-08-14 | ||
| 2023-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $199.00K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |